BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sherlock ME, MacDonald JK, Griffiths AM, Steinhart AH, Seow CH. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2015;26:CD007698. [PMID: 26497719 DOI: 10.1002/14651858.cd007698.pub3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Bonovas S, Nikolopoulos GK, Lytras T, Fiorino G, Peyrin-Biroulet L, Danese S. Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: Systematic review and network meta-analysis. Br J Clin Pharmacol 2018;84:239-51. [PMID: 29057539 DOI: 10.1111/bcp.13456] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
2 Abdalla MI, Herfarth H. Budesonide for the treatment of ulcerative colitis. Expert Opin Pharmacother. 2016;17:1549-1559. [PMID: 27157244 DOI: 10.1080/14656566.2016.1183648] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
3 Chen Y, Sun M. Preliminary evidence in treatment of eosinophilic gastroenteritis in children: A case series. World J Clin Cases 2022; 10(19): 6417-6427 [DOI: 10.12998/wjcc.v10.i19.6417] [Reference Citation Analysis]
4 Guariso G, Gasparetto M. Treating children with inflammatory bowel disease: Current and new perspectives. World J Gastroenterol 2017; 23(30): 5469-5485 [PMID: 28852307 DOI: 10.3748/wjg.v23.i30.5469] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
5 Nardelli S, Pisani LF, Tontini GE, Vecchi M, Pastorelli L. MMX® technology and its applications in gastrointestinal diseases. Therap Adv Gastroenterol 2017;10:545-52. [PMID: 28804515 DOI: 10.1177/1756283X17709974] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Zhao J, Zhang B, Mao Q, Ping K, Zhang P, Lin F, Liu D, Feng Y, Sun M, Zhang Y, Li QH, Zhang T, Mou Y, Wang S. Discovery of a Colon-Targeted Azo Prodrug of Tofacitinib through the Establishment of Colon-Specific Delivery Systems Constructed by 5-ASA-PABA-MAC and 5-ASA-PABA-Diamine for the Treatment of Ulcerative Colitis. J Med Chem 2022. [PMID: 35275619 DOI: 10.1021/acs.jmedchem.1c02166] [Reference Citation Analysis]
7 Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H, Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB; IBD guidelines eDelphi consensus group. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019;68:s1-s106. [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484] [Cited by in Crossref: 617] [Cited by in F6Publishing: 451] [Article Influence: 205.7] [Reference Citation Analysis]
8 Vetter M, Neurath MF. Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges. Therap Adv Gastroenterol 2017;10:773-90. [PMID: 29051788 DOI: 10.1177/1756283X17727388] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 3.6] [Reference Citation Analysis]
9 Bonovas S, Nikolopoulos GK, Piovani D, González-Lorenzo M, Pantavou K, Lytras T, Peyrin-Biroulet L, Danese S. Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis. Br J Clin Pharmacol 2019;85:2244-54. [PMID: 31269287 DOI: 10.1111/bcp.14051] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
10 Pandey M, Choudhury H, D/O Segar Singh SK, Chetty Annan N, Bhattamisra SK, Gorain B, Mohd Amin MCI. Budesonide-Loaded Pectin/Polyacrylamide Hydrogel for Sustained Delivery: Fabrication, Characterization and In Vitro Release Kinetics. Molecules 2021;26:2704. [PMID: 34062995 DOI: 10.3390/molecules26092704] [Reference Citation Analysis]
11 Dubois-Camacho K, Ottum PA, Franco-Muñoz D, De la Fuente M, Torres-Riquelme A, Díaz-Jiménez D, Olivares-Morales M, Astudillo G, Quera R, Hermoso MA. Glucocorticosteroid therapy in inflammatory bowel diseases: From clinical practice to molecular biology. World J Gastroenterol 2017; 23(36): 6628-6638 [PMID: 29085208 DOI: 10.3748/wjg.v23.i36.6628] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 43] [Article Influence: 10.6] [Reference Citation Analysis]
12 Maconi G, Camatta D, Cannatelli R, Ferretti F, Carvalhas Gabrielli A, Ardizzone S. Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety. Ther Clin Risk Manag 2021;17:285-92. [PMID: 33854320 DOI: 10.2147/TCRM.S263835] [Reference Citation Analysis]
13 Maconi G, Mezzina N, Landi S, Grillo S, Bezzio C, Bosani M, Pastorelli L, Dell'Era A, Chibbar R, Carmagnola S, Molteni P, Cassinotti A, Massari A, Ardizzone S. Use, effectiveness and tolerability of budesonide-MMX in ulcerative colitis: A real-life experience. United European Gastroenterol J 2019;7:1164-70. [PMID: 31700629 DOI: 10.1177/2050640619864257] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
14 Pai RK, Geboes K. Disease activity and mucosal healing in inflammatory bowel disease: a new role for histopathology? Virchows Arch. 2018;472:99-110. [PMID: 28555281 DOI: 10.1007/s00428-017-2156-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
15 Blackwell J, Selinger C, Raine T, Parkes G, Smith MA, Pollok R. Steroid use and misuse: a key performance indicator in the management of IBD. Frontline Gastroenterol 2021;12:207-13. [PMID: 33907617 DOI: 10.1136/flgastro-2019-101288] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Annese V. An update on treatment of ulcerative colitis. Expert Opinion on Orphan Drugs 2019;7:295-304. [DOI: 10.1080/21678707.2019.1638249] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Greenberg S, Herfarth HH, Barnes EL. Predictors of Inadequate Response to Budesonide Multimatrix in Real-World Patients with Ulcerative Colitis. Inflamm Intest Dis 2019;4:115-22. [PMID: 31559263 DOI: 10.1159/000501004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020; 26(43): 6710-6769 [PMID: 33268959 DOI: 10.3748/wjg.v26.i43.6710] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
19 Ivashkin VT, Shelygin YA, Belousova EA, Abdulganieva DI, Alekseeva OA, Achkasov SI, Valuiskikh EY, Vardanyan AV, Veselov AV, Veselov VV, Golovenko OV, Gubonina IV, Zhigalova TN, Kashnikov VN, Knyazev OV, Makarchuk PA, Moskaliev AI, Nanaeva BA, Nizov AA, Nikitina NV, Nikolaeva NN, Pavlenko VV, Poluektova EA, Svetlova IO, Tarasova LV, Tkachev AV, Frolov SA, Khlynova OV, Chashkova EY, Shapina MV, Sheptulin AA, Shifrin OS, Shchukina OB. PROJECT: CLINICAL GUIDELINES FOR THE DIAGNOSTICS AND TREATMENT OF ULCERATIVE COLITIS. Koloproktologiâ 2019;18:7-36. [DOI: 10.33878/2073-7556-2019-18-4-7-36] [Cited by in Crossref: 16] [Cited by in F6Publishing: 1] [Article Influence: 5.3] [Reference Citation Analysis]
20 Danese S, Banerjee R, Cummings JF, Dotan I, Kotze PG, Leong RWL, Paridaens K, Peyrin-Biroulet L, Scott G, Assche GV, Wehkamp J, Yamamoto-Furusho JK. Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy-Access to Rapid Treatment (iSTART) approach. Intest Res 2018;16:522-8. [PMID: 30321913 DOI: 10.5217/ir.2018.00073] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
21 Vanga R, Long MD. Contemporary Management of Ulcerative Colitis. Curr Gastroenterol Rep. 2018;20:12. [PMID: 29589185 DOI: 10.1007/s11894-018-0622-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
22 Euers L, Abughazaleh S, Glassner K, Gajula P, Jones-Pauley M, Ezeana C, Puppala M, Wang L, Wong S, Oglat A, Nickerson S, Abraham BP. Risk Factors for and Frequency of CT Scans, Steroid Use, and Repeat Visits in Inflammatory Bowel Disease Patients Seen at a Single-Center Emergency Department: A Retrospective Cohort Study. J Clin Med 2021;10:2679. [PMID: 34204580 DOI: 10.3390/jcm10122679] [Reference Citation Analysis]